Search
Life Sciences
Phase1/2 clinical trials in patients with follicular lymphoma and marginal zone lymphoma expected to begin in Q2 2021
ENTEROME SA, a clinical stage biopharmaceutical...
MaaT Pharma announced today positive topline results from its Phase 2 clinical trial evaluating lead microbiome ecosystem therapy, MaaT013, in a high-risk patient population...
A leading clinical-stage company developing a new category of therapies for immune-mediated diseases basedon rationally defined consortia of human microbiome-derived bacteria,...
Seventure Partners, one of Europe’s leaders in financing innovation and a world leader in life science microbiome investment, has increased focus on skin microbiome...
Pioneering a full-ecosystem microbiota approach to improve survival outcomes in life-threatening diseases by Hervé Affagard (Maat Pharma) published on...
MaaT Pharma announced today that it treated its first patient in a Phase 1 clinical trial to evaluate the safety and tolerability of MaaT033, a capsule formulation of the...
A consumer dermatology company developing novel, personalized, microbiome-based solutions for acne and other skin conditions, announced today that it has closed a $6.73 million...
BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the...
Federation Bio, a microbial therapeutics company targeting diseases in which the human microbiome can play a curative role, today announced that it has closed a $50 million...
ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today...
